LENZ
LENZ Therapeutics, Inc. NASDAQ Listed Mar 22, 2024$9.72
Mkt Cap $304.8M
52w Low $8.25
3.5% of range
52w High $50.40
50d MA $10.47
200d MA $24.25
P/E (TTM)
-3.1x
EV/EBITDA
-4.8x
P/B
0.9x
Debt/Equity
0.0x
ROE
-28.9%
P/FCF
-6.6x
RSI (14)
—
ATR (14)
—
Beta
2.29
50d MA
$10.47
200d MA
$24.25
Avg Volume
942.1K
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
CIK (SEC)
Phone
(858) 925-7000
445 Marine View Avenue · Solana Beach, CA 92014 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.91 | -1.16 | -27.5% | 9.03 | +1.8% | +0.4% | -1.4% | -6.0% | -1.3% | +10.4% | — |
| Nov 5, 2025 | AMC | -0.67 | -0.59 | +11.9% | 21.47 | +3.0% | +6.9% | +0.0% | +1.0% | +14.1% | -3.6% | — |
| Jul 30, 2025 | AMC | -0.58 | -0.53 | +8.6% | 30.76 | -0.7% | -3.2% | +0.6% | -2.1% | +3.9% | -1.0% | — |
| May 7, 2025 | AMC | -0.55 | -0.53 | +3.6% | 25.34 | +0.0% | +2.1% | +1.8% | +11.5% | -1.4% | -4.6% | — |
| Mar 19, 2025 | AMC | -0.42 | -0.46 | -9.5% | 25.52 | +8.0% | +3.1% | +0.7% | +0.6% | -0.9% | -1.3% | — |
| Nov 6, 2024 | AMC | -0.47 | -0.38 | +19.1% | 32.23 | -0.7% | +0.9% | +7.8% | +1.9% | +4.2% | -2.4% | — |
| Aug 14, 2024 | AMC | -0.49 | -0.40 | +18.4% | 23.50 | +1.1% | -3.8% | +0.7% | -0.2% | -0.9% | -0.1% | — |
| May 8, 2024 | AMC | -0.84 | -3.53 | -320.2% | 16.18 | -1.6% | -4.8% | +2.1% | +1.1% | -1.2% | +0.8% | — |
| Feb 27, 2024 | AMC | -0.13 | -0.40 | -207.7% | 14.96 | +2.5% | +3.7% | +3.4% | +0.0% | -2.1% | -2.7% | — |
| Nov 13, 2023 | AMC | -0.25 | -0.19 | +24.0% | 10.89 | +2.1% | +1.3% | -3.4% | +0.2% | +3.4% | +0.8% | — |
| Jun 29, 2023 | AMC | -6.79 | -6.82 | -0.5% | 12.26 | +0.7% | +0.4% | +1.9% | -0.7% | +1.8% | +2.3% | — |
| Mar 30, 2023 | AMC | -2.41 | -3.00 | -24.5% | 11.41 | +0.4% | +1.7% | +3.2% | -1.9% | +0.8% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.13 | $10.12 | -0.1% | -2.6% | +1.2% | -8.4% | +2.5% | +4.1% |
| Mar 26 | Citigroup | Maintains | Buy → Buy | — | $9.07 | $8.91 | -1.8% | -1.4% | -6.0% | -1.3% | +10.4% | +2.2% |
| Mar 25 | BofA Securities | Maintains | Buy → Buy | — | $9.03 | $9.19 | +1.8% | +0.4% | -1.4% | -6.0% | -1.3% | +10.4% |
| Oct 20 | Raymond James | Maintains | Outperform → Outperform | — | $38.26 | $39.17 | +2.4% | -5.1% | -7.6% | -2.6% | -4.0% | +1.9% |
| Oct 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.25 | $46.75 | +1.1% | -16.1% | -0.5% | +0.5% | +7.9% | -3.3% |
| Aug 1 | Citigroup | Maintains | Buy → Buy | — | $29.77 | $30.01 | +0.8% | +0.6% | -2.1% | +3.9% | -1.0% | +6.5% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.77 | $30.01 | +0.8% | +0.6% | -2.1% | +3.9% | -1.0% | +6.5% |
| Jul 31 | Citigroup | Maintains | Buy → Buy | — | $30.76 | $30.55 | -0.7% | -3.2% | +0.6% | -2.1% | +3.9% | -1.0% |
| Jul 31 | Raymond James | Maintains | Outperform → Outperform | — | $30.76 | $30.55 | -0.7% | -3.2% | +0.6% | -2.1% | +3.9% | -1.0% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.62 | $33.35 | +5.5% | -0.3% | +0.5% | -2.9% | -3.2% | +0.6% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.34 | $25.34 | +0.0% | +2.1% | +1.8% | +11.5% | -1.4% | -4.6% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.89 | $23.35 | -2.3% | -3.5% | +3.3% | +1.2% | +7.0% | +4.5% |
| Apr 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $20.26 | $21.29 | +5.1% | +14.7% | +2.8% | -3.5% | +3.3% | +1.2% |
| Mar 20 | Citigroup | Maintains | Buy → Buy | — | $25.52 | $27.57 | +8.0% | +3.1% | +0.7% | +0.6% | -0.9% | -1.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.23 | $32.00 | -0.7% | +0.9% | +7.8% | +1.9% | +4.2% | -2.4% |
| Aug 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.50 | $23.75 | +1.1% | -3.8% | +0.7% | -0.2% | -0.9% | -0.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.50 | $23.75 | +1.1% | -3.8% | +0.7% | -0.2% | -0.9% | -0.1% |
No insider trades available.
Data updated apr 25, 2026 6:51pm
· Source: massive.com